Zioptan (tafluprost) dosing, indications, interactions, adverse effects, and more

Sections

Sections tafluprost
Dosing & Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

ophthalmic solution

0.0015% (0.015mg/mL)

Elevated Intraocular Pressure

Indicated for reducing elevated IOP in patients with open-angle glaucoma or ocular hypertension

Instill 1 drop in affected eye(s) once daily in the evening

Administration

Instill into conjunctival sac of affected eye(s)

Do not exceed once daily dosing regimen; more frequent administration of prostaglandin analogs may lessen the IOP lowering effect

Reduction of intraocular pressure starts approximately 2 - 4 hours after first administration with maximum effect reached after 12 hr

If other topical ophthalmics are prescribed, each should be administered 5 minutes apart

Preservative free product; use immediately after opening one unit-dose for administration; sterility cannot be maintained after opening

Not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use

Interaction Checker

Enter a drug name and tafluprost

No Results

No Interactions Found

Interactions Found

Contraindicated

Serious - Use Alternative

Significant - Monitor Closely

Minor

All Interactions Sort By:

Due to system maintenance, the drug interactions feature you are attempting to access is temporarily unavailable. Please try again later.

>10%

Conjunctival hyperemia (4-20%)

1-10%

Ocular stinging (7%)

Ocular pruritus/allergic conjunctivitis (5%)

Cataract (3%)

Growth of eyelashes (2%)

Blurred vision (2%)

Postmarketing Reports

Periorbital and lid changes including deepening of the eyelid sulcus observed with prostaglandin analogs

Eye disorders: Iritis/uveitis

Respiratory disorders: Exacerbation of asthma, dyspnea

Contraindications

None

Cautions

Causes changes to pigmented tissues; most frequently reported changes have been of the iris, eyelid, and eyelashes; pigmentation changes of the iris is likely permanent Increases length, color, thickness, and number of eyelashes

Caution with active intraocular inflammation (may exacerbate condition)

Macular edema reported; caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or with known risk factors for macular edema

Pregnancy & Lactation

Pregnancy Category: C; teratogenic when administered IV in rats and rabbits

Lactation: Unknown whether distributed in breast milk

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Prostaglandin analog; exact mechanism by which it reduces IOP is unknown, but it is thought to increase uveoscleral outflow

Absorption

Bioavailability: Absorbed through the cornea

Onset: 2-4 hr; peak effect at 12 hr

Peak Plasma Time: 10 minutes

Peak Plasma Concentration: 26 pg/mL

AUC: 394-432 pg•min/mL

Metabolism

Tafluprost is an ester prodrug that is metabolized by hydrolysis to the biologically active acid metabolite (tafluprost acid)

Elimination

Mean plasma concentration of tafluprost acid were below the limit of quantification (ie, 10 pg/mL) at 30 minutes following topical ocular administration

BRAND	FORM.	UNIT PRICE	PILL IMAGE
Zioptan (PF) ophthalmic (eye) -	0.0015 % liquid

Patient Handout

No Patient Handout Available

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

View the formulary and any restrictions for each plan.
Manage and view all your plans together – even plans in different states.
Compare formulary status to other drugs in the same class.
Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier	Description
1	This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2	This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC	NOT COVERED – Drugs that are not covered by the plan.

Code	Definition
PA	Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL	Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST	Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR	Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]